Clinical Trials
5
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Pharmacokinetics, Safety and Efficacy Study of Recombinant Antithrombin Versus Placebo in Preterm Preeclampsia
- Conditions
- Preeclampsia
- First Posted Date
- 2014-02-11
- Last Posted Date
- 2017-08-09
- Lead Sponsor
- rEVO Biologics
- Target Recruit Count
- 120
- Registration Number
- NCT02059135
- Locations
- 🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸University of South Alabama, Mobile, Alabama, United States
🇺🇸University of Arkansas, Little Rock, Arkansas, United States
Phase III Study of Coagulation FVIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors
- Conditions
- Hemophilia A With InhibitorsHemophilia B With Inhibitors
- First Posted Date
- 2013-12-24
- Last Posted Date
- 2017-06-14
- Lead Sponsor
- rEVO Biologics
- Target Recruit Count
- 27
- Registration Number
- NCT02020369
- Locations
- 🇺🇸
Orthopaedic Hemophilia Treatment Center, Los Angeles, California, United States
🇺🇸University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
🇺🇸University of Colorado Hemophilia and Thrombosis Center, Aurora, Colorado, United States
A Phase I Safety, Pharmacokinetics and Pharmacodynamics Study of Recombinant Factor VIIa in Adult Patients With Hemophilia A or B
- Conditions
- Hemophilia
- First Posted Date
- 2012-10-17
- Last Posted Date
- 2013-07-30
- Lead Sponsor
- rEVO Biologics
- Target Recruit Count
- 15
- Registration Number
- NCT01708564
- Locations
- 🇺🇸
UC Davis Health System Internal Medicine: Hematology & Oncology, Sacramento, California, United States
🇺🇸RUSH Hemophilia & Thrombophilia Center, Chicago, Illinois, United States
🇳🇱Centre for Human Drug Research, Leiden, Netherlands
Recombinant Human Antithrombin (rhAT) in Patients With Hereditary Antithrombin Deficiency Undergoing Surgery or Delivery
- Conditions
- Antithrombin III Deficiency
- First Posted Date
- 2005-05-11
- Last Posted Date
- 2012-08-17
- Lead Sponsor
- rEVO Biologics
- Target Recruit Count
- 18
- Registration Number
- NCT00110513
Assess Incidence of Deep Vein Thrombosis(DVT)Following Administration of Recombinant Human Antithrombin (rhAT) to Hereditary Antithrombin(AT) Deficient Patients in High Risk Situations.
- Conditions
- Antithrombin Deficiency, Congenital
- First Posted Date
- 2003-03-18
- Last Posted Date
- 2012-10-16
- Lead Sponsor
- rEVO Biologics
- Target Recruit Count
- 14
- Registration Number
- NCT00056550